Partnership between the AP-HM and the start-up Poietis for a clinical trial of bio-printed skin

[ad_1]

It will be an "autologous dermo-epidermal substitute that will be applicable to all people who have suffered a loss of skin substance", and this, whatever the cause, is indicated.

"The aim is to produce implantable grafts directly from a simple biopsy performed during a consultation within a reasonable time" and "applicable without anesthesia, without complex surgical procedure", praised AP-HM.

The AP-HM did not indicate a date for the start of the trial, but expects that the production of grafts will be "very short".

A study, published on December 23, 2017 in the French Pharmaceutical Annals and carried out by six researchers from the pharmacy department of the European Hospital Georges-Pompidou (HEGP, AP-HP, Paris) and the research and reception group in law and health economics (Grades) of the Faculty of Pharmacy of the University of Paris-Sud, demonstrated that the use of 3D printing is confirmed in health establishments, we recall.

[ad_2]